Description

Overview

AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (hGH). It was developed as an experimental compound for metabolic and obesity research, with the goal of promoting fat metabolism without the broader effects of full-length growth hormone.

Potential Benefits Under Research

AOD9604 has been investigated for:

• Fat metabolism and lipolysis
• Body-weight management
• Adipose-tissue metabolism
• Energy metabolism
• Metabolic research related to obesity

Animal studies have reported increased lipolysis and reduced weight gain, but these findings should not be interpreted as proven weight-loss effects in humans.

How It May Work

AOD9604 was designed from the lipolytic portion of human growth hormone. Research suggests it may influence pathways involved in fat breakdown and lipid metabolism without functioning like full-length HGH through the complete GH/IGF-1 system.

Strength

AOD9604 5 mg indicates a stated product quantity of 5 mg. It is not an FDA-approved human dose, and there is no FDA-approved dosing regimen for AOD9604. FDA has evaluated AOD9604-related substances in the context of compounded products and concluded that the available evidence did not support adding them to the 503A bulk-drug list.

Safety

Human safety and effectiveness remain insufficiently established for routine medical use. Additional concerns for peptide products include:

• Immunogenicity
• Peptide aggregation
• Peptide-related impurities
• Product purity and characterization
• Unknown long-term effects

These issues are specifically noted in FDA’s evaluation of AOD9604.

Regulatory Status

AOD9604 is not an FDA-approved drug for weight loss or any other medical indication. It remains an investigational compound.

Conclusion

AOD9604 5 mg is an experimental peptide primarily associated with fat-metabolism and obesity research. While preclinical studies have produced interesting findings, its clinical effectiveness for weight loss has not been established, and 5 mg should be regarded as a product quantity rather than a validated therapeutic dose.